Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2010
05/27/2010WO2010060037A2 Adamantane modulators of nmda receptor and/or 5ht3 receptor
05/27/2010WO2010060030A1 Tlr ligand-nucleic acid nanostructure as a novel immune modulatory agent and method of using the same
05/27/2010WO2010060018A1 Azo and diaza derivatives and uses thereof in phototherapy
05/27/2010WO2010059969A2 Anti-angiogenesis therapy for the treatment of breast cancer
05/27/2010WO2010059967A2 Amide inhibitors of renin
05/27/2010WO2010059953A1 Quinazoline inhibitors of bace 1 and methods of using
05/27/2010WO2010059943A2 Fluorination of organic compounds
05/27/2010WO2010059942A1 Inhibition of apoe cleavage activity in the treatment of apoe-related disorders
05/27/2010WO2010059922A1 Pyrrolidine carboxamide compounds
05/27/2010WO2010059916A2 Preparation of docetaxel
05/27/2010WO2010059913A2 Preparation of rasagiline and salts thereof
05/27/2010WO2010059894A1 Ocular formulations of norketotifen
05/27/2010WO2010059859A1 Tgr5 modulators and methods of use thereof
05/27/2010WO2010059858A1 Manassantin compounds and methods of making and using same
05/27/2010WO2010059853A1 Tgr5 modulators and method of use thereof
05/27/2010WO2010059844A1 Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
05/27/2010WO2010059836A1 Substituted aza-bridged bicyclics for cardiovascular and cns disease
05/27/2010WO2010059795A1 Novel forms of an indazolo [5,4-a] pyrrolo [3,4-c] carbazole compound
05/27/2010WO2010059788A1 Pyrazolopyridine pi3k inhibitor compounds and methods of use
05/27/2010WO2010059773A1 Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
05/27/2010WO2010059771A1 Substituted pyrrolo[2,3-b]-pyridines and-pyrazines
05/27/2010WO2010059719A2 Dimeric 1-arylpyrazole derivatives
05/27/2010WO2010059717A2 Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol
05/27/2010WO2010059711A1 Sigma-1 receptor ligands and methods of use
05/27/2010WO2010059706A2 Translation factors as anti-aging drug targets
05/27/2010WO2010059668A1 A triazolothiadiazole inhibitor of c-met protein kinase
05/27/2010WO2010059667A1 Pharmaceutical composition of a potent hcv inhibitor for oral administration
05/27/2010WO2010059662A2 Constitutive androstane receptor (car) as a therapeutic target for obesity and type two diabetes
05/27/2010WO2010059658A1 Chemical compounds
05/27/2010WO2010059639A2 Hydroxyadamantyl inhibitors of dipeptidylpeptidase iv
05/27/2010WO2010059633A2 Compounds for treating parasitic disease
05/27/2010WO2010059628A1 Water-soluble formulations of resveratrol and uses thereof
05/27/2010WO2010059627A1 Polar quinazolines as liver x receptors ( lxrs ) modulators
05/27/2010WO2010059618A1 Adamantyl benzamide compounds
05/27/2010WO2010059611A2 Inhibitors of diacylglycerol acyltransferase
05/27/2010WO2010059610A1 6, 7 -dihydro- 5h- pyrrolo [3, 4-d] pyrimidin-4-yl] -quinolin-3 -ylamine compounds useful as faah modulators and uses thereof
05/27/2010WO2010059593A1 Methods and compositions for treatment of ophthalmic conditions
05/27/2010WO2010059589A1 Anticancer combination comprising docetaxel and an antisense oligonucleotide
05/27/2010WO2010059575A2 Combination therapy for the treatment of cancer
05/27/2010WO2010059561A2 Systems and methods for treatment of aneurysms using zinc chelator(s)
05/27/2010WO2010059555A1 Prolyl hydroxylase inhibitors
05/27/2010WO2010059552A1 Prolyl hydroxylase inhibitors
05/27/2010WO2010059549A1 Prolyl hydroxylase inhibitors
05/27/2010WO2010059531A2 Alpha-keto peracids and methods for producing and using the same
05/27/2010WO2010059529A2 Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof
05/27/2010WO2010059506A1 Directly compressible high functionality granular dibasic calcium phosphate based co-processed excipient
05/27/2010WO2010059504A1 Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
05/27/2010WO2010059473A2 Compositions and methods for alleviating skin disorders
05/27/2010WO2010059418A1 Substituted triazine and purine compounds, methods of inhibiting cruzain and rhodesain and methods of treating chagas disease and african trypanosomiasis
05/27/2010WO2010059401A2 Compounds that expand hematopoietic stem cells
05/27/2010WO2010059393A1 Serotonin receptor modulators
05/27/2010WO2010059390A1 Modulators of serotonin receptor
05/27/2010WO2010059385A1 Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidne derivatives useful as gdir agonists
05/27/2010WO2010059384A1 Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists
05/27/2010WO2010059372A2 Tryptase enzyme inhibiting aminopyridines
05/27/2010WO2010059259A1 Process for recovering florfenicol from pharmaceutical compositions
05/27/2010WO2010059253A2 Methods and compositions for localized agent delivery
05/27/2010WO2010059245A2 Compositions and methods for treating or preventing radiation injury
05/27/2010WO2010059244A2 Method for reducing thrombocytopenia and thrombocytopenia-associated mortality
05/27/2010WO2010059241A2 Treatment of amyotrophic lateral sclerosis
05/27/2010WO2010059239A2 Lactate salt of 4-(6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders
05/27/2010WO2010059215A1 Novel antithrombotic diadenosine tetraphosphates and related analogs
05/27/2010WO2010059142A1 Anthraquinone dioximes and uses thereof
05/27/2010WO2010059135A1 Anti-cancer microparticle
05/27/2010WO2010059119A1 A combination of tert -butyl (2-{7- [2- (4-cyano-2- f luorophenoxy) ethyl] -9-oxa-3, 7-diazabicyclo [3.3.1] non-3- yl } ethyl) carbamate and certain antiarrhythmic benzofurans
05/27/2010WO2010059038A2 Wet granulation of tenofovir, emtricitabine and efavirenz
05/27/2010WO2010059004A2 Chemical inhibitor of p53-snail binding and pharmaceutical composition for treating cancer disease containing same as its active ingredient
05/27/2010WO2010059001A2 Polymer micelle composition for treatment of resistant cancer cells
05/27/2010WO2010058936A2 Skin external composition for inhibiting epidermal hyperproliferation and alleviating inflammatory skin diseases containing ortho-dihydroxyisoflavone derivatives
05/27/2010WO2010058926A2 Pharmaceutical composition containing ginger extract or shogaol
05/27/2010WO2010058858A1 Novel pyrazole-3-carboxamide derivative having 5-ht2b receptor antagonist activity
05/27/2010WO2010058853A1 Ceramide dispersion, and process for producing same
05/27/2010WO2010058846A1 4,6-diaminonicotinamide compound
05/27/2010WO2010058844A1 Adhesive material containing 5-methyl-1-phenyl-2-(1h)-pyridone
05/27/2010WO2010058824A1 Substance for regulating differentiation into mesenchymal cell, and use thereof
05/27/2010WO2010058795A1 Antioxidant
05/27/2010WO2010058794A1 Antioxidant
05/27/2010WO2010058779A1 Therapeutic agent for chorioretinal degenerative diseases comprising pyridine-3-carbaldehyde o-(piperidin-1-yl-propyl)-oxime derivative as active ingredient
05/27/2010WO2010058751A1 Pharmacologically acceptable salt of [1,3,4]oxadiazole compound or hydrate thereof
05/27/2010WO2010058730A1 Anti-wrinkle agents
05/27/2010WO2010058669A1 Novel prostaglandin e1 derivative, and nanoparticle having same encapsulated therein
05/27/2010WO2010058572A1 Methods for diagnosing or treating prostate cancer
05/27/2010WO2010058512A1 Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives
05/27/2010WO2010058426A2 Inhibition of vegf-a secretion, angiogenesis and/or neoangiogenesis by sina mediated knockdown of vegf-c and rhoa
05/27/2010WO2010058417A1 Isoxazole/isoxazoline/combretastatin linked dihydroquinazolinone hybrids as potential anticancer agents and process for the preparation thereof
05/27/2010WO2010058416A1 Quinazolinone linked pyrrolo[2,1 -c][1.4]benzodiazepine hybrids as potential anticancer agents and process forthe preparation thereof
05/27/2010WO2010058414A1 Novel pyrroiol2,l-cu1.41benzodiazepine derivatives with dithiocarbamate side chains and process for the preparation thereof
05/27/2010WO2010058402A1 Novel anti-biofilm agents
05/27/2010WO2010058353A1 Novel bis-amides as antimalarial agents
05/27/2010WO2010058349A1 Pharmaceutical composition for topical application
05/27/2010WO2010058333A1 Lactams as beta secretase inhibitors
05/27/2010WO2010058318A1 1-oxa-8-azaspiro [4, 5 ] decane- 8 -carboxamide compounds as faah inhibitors
05/27/2010WO2010058314A1 Hydroxyquinolin-2(1h)-ones and derivatives thereof
05/27/2010WO2010058297A2 The use of ph-sensitive, acid-stable metal-binding nanoparticles
05/27/2010WO2010058280A1 Auto magnetic metal salen complex compound
05/27/2010WO2010058242A1 New formulations with anti-neoplastic activity
05/27/2010WO2010058166A1 Use of rimcazole for the treatment of ocular disorders
05/27/2010WO2010058104A2 Pharmaceutical compositions containing inulin as granulation carrier
05/27/2010WO2010058060A1 Aryl piperazine and their use as alpha2c antagonists
05/27/2010WO2010058032A2 New compounds
1 ... 2248 2249 2250 2251 2252 2253 2254 2255 2256 2257 2258 2259 2260 2261 2262 2263 2264 2265 2266 2267 2268 ... 7860